Separation, Characterization and Dose-Effect Relationship of the PPARγ-Activating Bio-Active Constituents in the Chinese Herb Formulation ‘San-Ao Decoction’

Ling Zhou ¹, Yu-Ping Tang ¹*, Lu Gao ², Xin-Sheng Fan ¹*, Chun-Mei Liu ¹ and De-Kang Wu ¹

¹ Jiangsu Key Laboratory for TCM Formulae Research, Nanjing University of Chinese Medicine, Nanjing 210046, China
² Nanjing Medical University, Nanjing 210029, China

* Authors to whom correspondence should be addressed; E-Mails: yupingtang@njutcm.edu.cn (Y-P.T.); ltcmf@njutcm.edu.cn (X-S.F.).

Received: 14 August 2009; in revised form: 9 September 2009 / Accepted: 29 September 2009 / Published: 9 October 2009

Abstract: San-ao decoction (SAD), comprising Herba Ephedrae, Radix et Rhizoma Glycyrrhizae and Seneb Armeniacae Amarum, is one of the most popular traditional Chinese medicine (TCM) formulae for asthma. Peroxisome proliferator-activated receptors (PPARs) are key regulators of lipid and glucose metabolism and have become important therapeutic targets for various diseases. PPARγ activation might exhibit anti-inflammatory properties in different chronic inflammatory processes. The EtOAc fraction of SAD showed a significant effect on PPARγ activation. A simple and rapid method has been established for separation and characterization of the main compounds in the PPARγ-activating fraction of SAD by ultra-fast HPLC coupled with quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF/MS). A total of 10 compounds were identified in the activating fraction of SAD, including amygdalin (1), liquiritin (2), 6′-acetyliquiritin (3), liquiritigenin (4), isoliquiritigenin (5), formononetin (6), licoisoflavanone (7), glycycoumarin (8), glycyrol (9) and quercetin (10). The results also characterized formononetin as a predominant component in this fraction. The dose-effect relationship comparison study of formononetin and the EtOAc fraction of SAD by adding formononetin was performed, the results suggested that formononetin was the major component of the EtOAc fraction of SAD responsible for activating PPARγ, and the
method will possibly be applied to study the complex biological active constituents of other TCMs.

**Keywords:** San-ao decoction; PPAR\(\gamma\); does-effect; UPLC; quatrope time-of-flight mass spectrometry

1. Introduction

Traditional Chinese medicines (TCMs) are natural therapeutic remedies used under the guidance of traditional Chinese medical philosophy and the Chinese community worldwide for thousands of years. Most of the TCMs are multi-ingredient formulae, and it is widely accepted that multiple constituents are responsible for their bio-activities [1]. However, due to the complexity of the chemical compositions of TCMs, the bioactive compounds and the therapeutic mechanisms of most TCMs are still unknown. Therefore, it is important and urgent to carry out chemical and pharmacological studies on TCMs.

San-ao decoction (SAD) is a well-known Chinese formula that has been used clinically to treat upper respiratory diseases such as colds and bronchitis for thousands of years. Nowadays, it is widely used in clinical practice for treating bronchitis caused by bacterial and viral infection. SAD decoction consists of three traditional Chinese medicines: Herba Ephedrae, Semen Armeniacae amarum, and Radix Glycyrrhizae, which are all recorded in the Chinese Pharmacopoeia [2].

The use of liquid chromatography-mass spectroscopy (LC/MS) is now commonplace, as the desire for significantly reduced analysis times with increased sample throughput, sensitivity, and resolution has resulted in the research of simultaneous determination on multiple compounds, such as the chemical research of formulae of TCMs [3,4]. Because of the high speed of analysis, sensitivity and confirmation of structural information, ultra-fast high performance liquid chromatograph (UPLC) system coupled with mass spectrometry has become the preferred analytical technique for herbal medicines [5-8]. Quatrope time-of-flight (Q-TOF) MS shows its unique advantages in providing high selectivity with narrow mass windows over nominal mass chromatograms, accurate mass measurements for elemental composition and structural information.

Peroxisome proliferator-activated receptors (PPARs), which were divided into three subtypes including \(\alpha\), \(\delta\) and \(\gamma\), are ligand-activated transcription factors of a nuclear receptor superfamily [9,10]. PPAR\(\gamma\) is thought to be involved in cell proliferation or carcinogenesis if it is ubiquitously expressed [11,12], and it is also known as potent agents in the treatment of type 2 diabetes, inflammatory diseases, and cancers [13,14]. PPAR\(\gamma\) belongs to the group of nuclear hormone receptors consisting of a ligand and DNA binding domain which, upon activation by their respective ligands, bind to specific PPAR response elements (PPREs) in the promoter of their target genes, thus regulating their expression. PPAR\(\gamma\) can be activated by naturally occurring ligands. PPAR\(\gamma\) is also a nuclear transcription factor originally described as a major regulator in glucose homeostasis and adipogenesis [10], but recent work has shown that PPAR\(\gamma\) activation might exhibit anti-inflammatory properties in different chronic inflammatory processes [15]. Previous work has shown inhibition of NF-kB
activation by PPARγ activators in various cell types such as endothelial cells and monocyte/macrophages [16,17].

In order to investigate the bio-active components of SAD, the activity of four fractions from SAD decoction on restoring glycemic balance induced by PPARγ was investigated. The results showed the EtOAc fraction had obvious biological activity. Then, a UPLC-Q-TOF/MS method was selected and developed for characterization of constituents in the active fraction of SAD for the first time, and the dose-effect relationship of the main bio-active constituent was also investigated in order to clarify the total bio-active contribution from the constituents.

2. Results and Discussion

2.1. Effect of the different fraction from SAD on PPARγ

The activities of nonaqueous fractions of SAD with cyclohexane, n-butyl alcohol extracted were similar, the ethyl acetate fraction showed obvious activity (Figure 1). Yields of these extracts obtained from cyclohexane, EtOAc, n-BuOH and water participation were 4.6, 1.3 and 4.8 g/100 g, respectively. The activities at 0.3 g/mL of the nonaqueous extracts of SAD were equivalent to 40 % of that at 0.5 μmol/L of T174, a synthetic potent PPARγ agonist.

Figure 1. Peroxisome proliferator-activated receptor PPARγ ligand-binding activity of SAD. a

![Figure 1](image)

a (0.3 mg/mL) of SAD extracts obtained with cyclohexane (SAD-2), EtOAc (SAD-3), n-BuOH (SAD-4), and Water (SAD-1) were assayed with a Luciferase Reporter Gene Assay system). Means with different letters differ, * P < 0.05; ** P < 0.01.

2.2. UPLC-Q-TOF/MS analysis of the fraction activating of PPARγ in SAD

A UPLC-ESI-MS/MS method was developed to separate and characterize the chemical constituents of the PPARγ-activating EtOAc fraction. Ten identified peaks were separated under the UPLC condition with UV detection, and the chromatography of MS total ion current (TIC) in negative mode was shown in Figure 2. The retention time, m/z value and UV maximum absorption wavelength of each peak was summarized in Table 1. Ten peaks were identified as amygdalin (1), liquiritin (2), 6′-acetyliquiritin (3), liquiritigenin (4), isoliquiritigenin (5), formononetin (6), licoisoflavanone (7),
glycycoumarin (8), glycyrol (9) and quercetin (10) by comparing the retention time, UV and ESI-MS spectra with authentic standards (Table 1, Figure 3). Chemical structures of the identified compounds are shown in Figure 3 and their MS/MS fragmentations are also shown in Table 1.

**Figure 2.** UPLC-Q-TOF/MS/MS analysis of the SAD EtOAc fraction.

(a) UPLC-UV chromatogram monitored at 254 nm, (b) LC-negative ion ESI-MS total ion current (TIC) profile, (c) LC-positive ion ESI-MS total ion current (TIC) profile. Peak identity: 1 = amygdalin, 2 = liquiritin, 3 = 6′-acetyliquiritin, 4 = liquiritigenin, 5 = isoliquiritigenin, 6 = formononetin, 7 = licoisoflavanone, 8 = glycycoumarin, 9 = glycyrol, 10 = quercetin.

**Table 1.** UPLC-Q-TOF/MS analysis of EtOAc fraction from SAD.

| Peak no. | Retention time (min) | MS² of fragment Ions | ESI-mass spectra [M-H]⁻ | Maximum absorption wavelength λmax (nm) | Identification |
|----------|----------------------|----------------------|--------------------------|----------------------------------------|----------------|
| 1        | 3.59                 | 385.14, 340.18, 237.08, 187.09, 165.05 | 456.15                   | 210, 252, 263, 269                     | amygdalin      |
| 2        | 4.39                 | 417.11, 366.11, 255.06, 151.04, 135.00 | 418.15                   | 241, 275, 327                         | liquiritin     |
| 3        | 5.73                 | 417.11, 255.06, 135.00 | 469.13                   | 230, 258, 277, 320                     | 6′-acetyliquiritin |
| 4        | 5.75                 | 135.01               | 255.07                   | 236, 272, 315                         | liquiritigenin |
| 5        | 7.68                 | 135.01               | 255.06                   | 240, 330, 395                         | isoliquiritigenin |
| 6        | 8.29                 | 255.06, 135.01       | 267.06                   | 248, 300                              | formononetin   |
| 7        | 10.17                | 297.20, 269.08       | 353.10                   | 227, 260, 330                         | licoisoflavanone |
| 8        | 10.59                | 353.11, 329.22, 183.02, 141.02 | 367.11                   | 236, 327, 370, 384                     | glycycoumarin |
| 9        | 11.79                | 335.10, 267.04       | 365.10                   | 229, 286, 351, 382                     | glycyrol       |
| 10       | 13.57                | 227.16               | 301.16                   | 254, 312                              | quercetin      |
2.3. Effect of ten compounds from EtOAc fraction on PPARγ

Furthermore, the activities of ten compounds (five concentrations for each compound) from the EtOAc fraction of SAD were evaluated, and the results (the optimum concentration for each compound) are shown in Figure 4. Liquiritin, isoliquiritigenin, glycycoumarin and formononetin (5 μm) showed significant activity.

2.4. Dose-effect relationship of formononetin in EtOAc fraction of SAD

Formononetin was completely removed from the EtOAc fraction of SAD using preparative HPLC; the results are shown in Figure 5. The dose-effect of formononetin is shown in Figure 6, the optimum concentration of formononetin was 1.34 μg/mL. When we gradually added formononetin into the EtOAc fraction from which the formononetin had already been removed the results showed almost the same trend as the dose-effect of formononetin. When the concentration of formononetin in the EtOAc fraction was up to 1.34 μg/mL, the activation effect on PPARγ was even better than that of
formononetin itself, and the activity of the EtOAc fraction (formononetin was 0.76 μg/mL) was also near that of formononetin (0.76 μg/mL). These results suggested that formononetin was possibly the major active component for the activation on PPARγ in the SAD EtOAc fraction.

**Figure 4.** Peroxisome proliferator-activated receptor PPARγ ligand-binding activity of ten identified compounds from the EtOAc of SAD. a

\[\text{Amygdaloside (4.57 μg/mL), liquiritigenin (3.84 μg/mL), liquiritin (4.19 μg/mL), isoliquiritigenin (2.56 μg/mL), formononetin (1.34 μg/mL), glycyrrol (2.93 μg/mL), licoioflavanone (3.54 μg/mL), glycycoumarin (3.68 μg/mL), acetyliquititin (7.05 μg/mL), quercetin (3.02 μg/mL). All of them were dissolved in DMSO. T174 at 0.5 μmol/L was used as a positive control, and dimethyl sulfoxide at 1 mL/L as a solvent control. Values are means ± SD (n = 3). Means with different letters differ, * P < 0.05; ** P < 0.01.}

**Figure 5.** UPLC-Q-TOF/MS/MS analysis of the EtOAc fraction of SAD before and after removing formononetin.

(a) the EtOAC fraction of SAD, (b) the EtOAc fraction of SAD after removing formononetin by using preparation liquid chromatography.
Figure 6. Dose-effect relationship of formononetin in the EtOAc fraction of SAD.

3. Experimental

3.1. Chemicals and reagents

HPLC grade methanol (Tedia, U.S.A.) was used for HPLC analysis. Reagent grade ethanol (Hanbang Company, Huaian, China) was used for extraction and separation. Amygdalin, liquiritin, 6’-acetylliquiritin, licoisoflavonone, glycycoumarin, glycyrol, quercetin were purchased from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). Liquiritigenin, isoliquiritigenin and formononetin were isolated in our laboratories.

3.2. Plant material

Herba Ephedrae (Ephedra sinica Stapf), Semen Armeniacae amarum (Prunus armwmiaca L.var. ansu Maxim.) and Radix Glycyrrhizae (Glycyrrhiza uralensis Fisch.) were collected from Shanxi, Hebei and Inner Mongolia, respectively. The crude herbs were identified by Dr. Wei Yue of the Nanjing University of Chinese Medicine.

3.3. Sample preparation

The sliced crude drug materials (900 g) were extracted twice with boiling water for 2 h each time. After removal of the solvent under reduced pressure to give the water extract, the residue was partitioned sequentially with cyclohexane, EtOAc and n-BuOH, respectively, to afford three fractions. Sample for UPLC/MS analysis: EtOAc fraction (100 mg) was dissolved in MeOH (10 mL). 1 μL of the solution was injected into the UPLC/MS analysis. Sample for isolation by preparation liquid chromatography: EtOAc fraction (5 g) was dissolved in MeOH (50 mL). All the solutions were injected into the chromatograph using 500 μL each time.
3.4. Equipment and chromatographic conditions

A Waters UPLC ACQUITY™ (Waters Company, U.S.A.) equipped with the MassLynx V4.1 software (Waters) and comprised of a quaternary solvent delivery pump, an online vacuum degasser, an autosampler, a thermostated compartment and a diode array detector, were used for the chromatographic analysis. All separations were carried out on an ACQUITY UPLC BEH C₁₈ column (2.1×100 mm, 1.7 μm, Waters). Mobile phase: A = water, and B = methanol. The elution was performed using a linear gradient of 2-10% B within 2 min, 10-30% B within 2-3 min, 30-80% B within 3-13 min, and 80-2% B at the last 2 min. The flow-rate was 0.3 mL min⁻¹. The temperature of column was 30 °C. The UV spectrum was recorded from 190 to 400 nm, and injection volume was 1 μL.

3.5. Mass spectrometric conditions

Waters Synapt Q-TOF-MS (Waters Company, USA) was connected to the Waters UPLC instrument via an ESI interface for UPLC-MS/MS analysis. Ultra high purity helium was used as the collision gas and high-purity nitrogen (N₂) as the makeup gas. The optimized parameters in the negative and positive ion mode were as follows: capillary, 3,000.0 V, sample cone, 35.0 V, desolvation temp, 200.0 °C, source temp, 100.0 °C, cone, 58 L·hr⁻¹, desolvation 500 L·hr⁻¹, collision energy, 35.0 (MS/MS), 5.0 (MS). For full scan MS analysis, the spectra were recorded in the range of m/z 100-1,000.

3.6. Equipment and conditions of preparative liquid chromatography

Preparative analysis was carried out on a Waters 2545 Binary Gradient Module with a Waters 2489 UV/Visible Detector, and Waters 2767 Sample Manager (Waters). Separation was achieved by using a SunFire Prep C₁₈ OBD column (30 mm × 150 mm, 5 μm, Waters) with a mobile phase of methanol-aqueous phase (containing 0.1% TFA) at a flow rate of 30 mL/min. The percentage of methanol in the mobile phase was programmed as follows: 60% (0 min) - 75% (10 min) - 100% (11 min) - 60% (12 min). The elution was carried out at ambient temperature. The injection volume was 800 μL.

3.7. Cell culture and full-length reporter-gene bioassays

Thiazolidinedione (T174), a specific ligand for PPARγ, was kindly provided by Tanabe Seiyaku (Osaka, Japan). It was diluted with dimethyl sulfoxide (DMSO) to prepare the stock solutions (10-100 mM). PPAR ligand-binding activity at 0.5 μmol/L of troglitazone was approximately three-fold of that of the solvent control. CHO, a Chinese hamster ovary cell line (from ATCC), was maintained on 24-well tissue culture plates containing the maintenance medium at 37 °C, in 5% CO₂. At 80% confluent, 1 μg/well of human PPARγ expression vector, pGL3-3xPPRE-luc plasmid, or control vector respectively was transfected into cells using a Lipofectamine Plus system (Invitrogen). As the negative control, human PPARγ expression vector and pGL3-3xPPRE-luc plasmid were transfected into the cell line. After transfection, the cells were cultured for 24 h, and compounds for ligand assay were added into the medium at appropriate concentrations. After additional 24 h
incubation, the cells were lysed for luciferase assay performed using a Luciferase Reporter Gene Assay system (Promega) according to the manufacturer’s protocol.

4. Conclusions

A UPLC-Q-TOF/mass method had been established for the first time for the separation and characterization of the main compounds in the SAD fraction activating PPARγ. A total of 10 compounds were identified in the activating SAD fraction, including isoliquiritigenin, formononetin and other flavonoids. The method could rapidly separate and elucidate complex constituents in TCMs, in comparison to other analysis method such as TLC and HPLC. The effects of the compounds and the EtOAc fraction of SAD for activating PPARγ were evaluated by the luciferase activity assay, and the results indicated that some isoflavones, especially formononetin, showed significant activity. Formononetin, a isoflavonoid found in high concentrations in leguminous plant, has been shown to reduce production of proinflammatory mediators in LPS-stimulated macrophages, fibroblasts, and intestinal epithelial cells. It was isolated from Pueraria thomsonii as the PPAR-activating compound [18]. The dose-effect relationship comparison study of formononetin and the EtOAc fraction of SAD by adding formononetin was performed, and the results suggested that formononetin was the major component of the EtOAc fraction of SAD responsible for activating PPARγ. The method could possibly be applied to study complex biological active constituents of other TCMs.

Acknowledgements

This research was financially supported by National 11th Five-Year Scientific and Technological Support Projects (2006BAI06A02-01); 2006 “Qing-Lan Project” Scientific and Technological Innovation Team Training Program of Jiangsu College and University.

References and Notes

1. Xue, T.; Roy, R. Studying traditional Chinese medicine. Science 2003, 300, 740-741.
2. The State Pharmacopoeia Commission of P.R. China. The Pharmacopoeia of the People’s Republic of China; Chemical Industry Publishing Press: Beijing, China, 2005; pp. 59, 140, 223.
3. Wang, Z.J.; Wo, S.K.; Wang, L.; Lau, C.B.S.; Lee, V.H.L.; Chow, M.S.S.; Zuo, Z. Simultaneous quantification of active components in the herbs and products of Si-Wu-Tang by high performance liquid chromatography-mass spectrometry. J. Pharm. Biomed. Anal. 2009, 50, 232-244.
4. Qi, L.W.; Cao, J.; Li, P.; Wang, Y.X. Rapid, sensitive quantitation of major constituents in Danggui Buxue Tang by ultrafast HPLC-TOF/MS. J. Pharm. Biomed. Anal. 2008, 49, 502-507.
5. Chen, X.J.; Ji, H.; Zhang, Q.W.; Tu, P.F.; Wang, Y.T.; Guo, B.L.; Li, S.P. A rapid method for simultaneous determination of 15 flavonoids in Epimedium using pressurized liquid extraction and ultra-performance liquid chromatography. J. Pharm. Biomed. Anal. 2008, 46, 226-235.
6. Li, X.; Xiong, Z.; Ying, X.; Cui, L.; Zhu, W.; Li, F. A rapid ultra-performance liquid chromatography-electrospray ionization tandem mass spectrometric method for the qualitative and
the quantitative analysis of the constituents of the flower of *Trollius ledibouri* Reichb. *Anal. Chim. Acta* **2006**, *580*, 170-180.

7. Yoshida, T.; Majors, R.E. High speed analyses using rapid resolution liquid chromatography on 1.8-μm porous particles. *J. Sep. Sci.* **2006**, **29**, 2421-2432.

8. Ren, L.; Xue, X.; Zhang F.; Xu Q.; Liang X. High performance liquid chromatography-mass spectrometry analysis of protoberberine alkaloids in medicine herb. *J. Sep. Sci.* **2007**, **30**, 833-842.

9. Kersten, S.; Desvergne, B.; Wahli, W. Roles of PPARs in health and disease. *Nature*** **2000**, *405*, 421-424.

10. Schoonjans, K.; Staels, B.; Auwerx, J. The peroxisome proliferator-activated receptor (PPARs) and their effects on lipid metabolism and adipocyte differentiation. *Biochim. Biophys. Acta* **1996**, **1302**, 93-109.

11. He, T.C.; Chan, T.A.; Vogelstein, B.; Kinzler, K.W. PPARδ is an APC-regulated target of nonsteroidal anti-inflammatory drugs. *Cell*** **1999**, *99*, 335-345.

12. Hansen, J.B.; Zhang, H.; Rasmussen, T.H.; Petersen, R.K.; Flindt, E.N.; Kristiansen, K. Peroxisome Proliferator-activated Receptor δ (PPARδ) –mediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signaling. *J. Biol. Chem.* **2001**, **276**, 3175-3182.

13. Rangwala, S.M.; Lazar, M.A. Peroxisome proliferator-activated receptor γ in diabetes and metabolism. *Trends Pharm. Sci.* **2004**, **25**, 331-336.

14. Murphy, G.J.; Holder, J.C. PPAR-γ agonists: therapeutic role in diabetes, in inflammation and cancer. *Trends Pharm. Sci.* **2000**, **21**, 469-474.

15. Clark, R.B. The role of PPARs in inflammation and immunity. *J. Leukoc. Biol.* **2002**, **71**, 388-400.

16. Marx, N.; Mach, F.; Sauty, A; Leung, J.H.; Sarafis, M.N.; Ransohoff, R.M.; Libby, P.; Plutzky, J.; Luster, A.D. PPARγ activators inhibit Interferon-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cells. *J. Immunol.* **2000**, **164**, 6503-6508.

17. Ricote, M.; Li, A.C.; Willson, T.M.; Kelly, C.J.; Glass, C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. *Nature*** **1998**, *391*, 79-82.

18. Shen, P.M.; Liu, H.T.; Ng, Y.; Chan, Y.H.; Yong, E.L. Differential effects of isoflavones, from *Astragalus membranaceus* and *Pueraria thomsonii*, on the activation of PPARα, PPARγ, and adipocyte differentiation in vitro. *J. Nutr.* **2006**, **136**, 899-905.

**Sample Availability:** Samples of compounds **1-10** are available from the authors.